IPC-klasse
Fullmektig i Norge:
Org.nummer: 982702887
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2009.04.10, US 168411 P
DIARRA DANIELLE ET AL: "Dickkopf-1 is a master regulator of joint remodeling" NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/NM1538, vol. 13, no. 2, 1 February 2007 (2007-02-01), pages 156-163, XP002486201 ISSN: 1078-8956 [retrieved on 2007-01-21] (B1)
ETTENBERG SETH A ET AL: "BHQ880, a novel anti-DKK1 neutralizing antibody, inhibits tumor-induced osteolytic bone disease" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 49, 1 April 2008 (2008-04-01), page 947, XP009134334 ISSN: 0197-016X (B1)
FILIPPO CARACI ET AL: "The Wnt Antagonist, Dickkopf-1, as a Target for the Treatment of Neurodegenerative Disorders" NEUROCHEMICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE LNKD- DOI:10.1007/S11064-008-9710-0, vol. 33, no. 12, 22 April 2008 (2008-04-22), pages 2401-2406, XP019647587 ISSN: 1573-6903 (B1)
FULCINITI MARIATERESA ET AL: "Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma" BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, UNITED STATES LNKD- DOI:10.1182/BLOOD-2008-11-191577, vol. 114, no. 2, 9 July 2009 (2009-07-09), pages 371-379, XP009134332 ISSN: 1528-0020 [retrieved on 2009-05-05] (B1)
GAVRIATOPOULOU MARIA ET AL: "Dickkopf-1: a suitable target for the management of myeloma bone disease." EXPERT OPINION ON THERAPEUTIC TARGETS JUL 2009 LNKD- PUBMED:19530987, vol. 13, no. 7, July 2009 (2009-07), pages 839-848, XP009134320 ISSN: 1744-7631 (B1)
HALL CHRISTOPHER L ET AL: "Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis" PROSTATE, WILEY-LISS, NEW YORK, NY, US LNKD- DOI:10.1002/PROS.20805, vol. 68, no. 13, 15 September 2008 (2008-09-15), pages 1396-1404, XP009134318 ISSN: 0270-4137 [retrieved on 2008-06-16] (B1)
ZHOU XIAO-LEI ET AL: "Downregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/beta-catenin signaling" ACTA PHARMACOLOGICA SINICA, vol. 31, no. 2, February 2010 (2010-02), pages 202-210, XP009134321 (B1)
KRAJ MARIA: "Multiple myeloma bone disease and novel anti-myeloma agents" ACTA HAEMATOLOGICA POLONICA, vol. 39, no. 2, 2008, pages 163-178, XP009134337 ISSN: 0001-5814 (B1)
TERPOS E: "Antibodies to dickkopf-1 protein" EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB LNKD- DOI:10.1517/13543776.16.10.1453, vol. 16, no. 10, 1 October 2006 (2006-10-01), pages 1453-1458, XP002486202 ISSN: 1354-3776 (B1)
WO-A1-2008/097510 (B1)
WO-A2-2006/015373 (B1)
WO-A2-2007/084344 (B1)
YACCOBY SHMUEL ET AL: "Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo" BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US LNKD- DOI:10.1182/BLOOD-2006-09-047712, vol. 109, no. 5, 1 March 2007 (2007-03-01) , pages 2106-2111, XP002486200 ISSN: 0006-4971 [retrieved on 2006-10-26] (B1)
HEATH DEBORAH J ET AL: "Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma" JOURNAL OF BONE AND MINERAL RESEARCH, AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH, NEW YORK, NY, US LNKD- DOI:10.1359/JBMR.081104, vol. 24, no. 3, 1 March 2009 (2009-03-01), pages 425-436, XP009134333 ISSN: 0884-0431 [retrieved on 2009-12-04] (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Batch Varsel om betaling av første årsavgift (3319)
|
Utgående
EP Registreringsbrev (3210)
|
Innkommende
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 16. avg. år (EP) | 2025.03.21 | 6760 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 15. avg. år (EP) | 2024.03.22 | 6310 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 14. avg. år (EP) | 2023.03.22 | 4500 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 13. avg. år (EP) | 2022.03.24 | 4200 | 1/ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 12. avg. år (EP) | 2021.03.25 | 3850 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 11. avg. år (EP) | 2020.03.27 | 3500 | MASTER DATA CENTER INC | Betalt og godkjent |
Årsavgift 10. avg. år (EP) | 2019.03.26 | 3200 | MASTER DATA INC | Betalt og godkjent |
Årsavgift 9. avg. år (EP) | 2018.03.23 | 2850 | MASTER DATA INC | Betalt og godkjent |
31716636 expand_more expand_less | 2017.10.24 | 5500 | Zacco Norway AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|